Organisational Capacity Building

Make your patient organisation stronger by learning practical tools, skills, and strategies. This section provides the resources you need to improve your services, engage your community, advocate effectively, and grow sustainably. Whether you are developing new programmes, improving communication, or shaping organisational strategy, you will find the guidance you need to build stronger and more impactful structures.

Order by

Categories

Advocacy, Campaigning & Public Influence
How can patient organisations drive change and influence decision-makers.
Research, Evidence and Learning
How can patients organisations use data to build evidence, contribute to research, and build knowledge.
Services and Community Support Provided by Patient Organisations
How can patient organisations support their members and people affected by MS, NMOSD, MOGAD and other related conditions.

MCB: Effective Campaigning with MS Societies

The Workshop on Effective Campaigning: Turning campaigning efforts into success with the right engagement, stakeholders, and alliances, part of EMSP’s…

MCB: Effective campaigning

The Workshop on Effective campaigning , part of EMSP’s Membership Capacity Building (MCB) Programme, was held in 2022. It brought…

MCB: Engaging with young people and recently diagnosed

The Workshop on Engaging with Young People and recently diagnosed, part of EMSP’s Membership Capacity Building (MCB) Programme, was held…

MCB: Driving Impact: Uniting for MS Policy Change across the EU and National level

The Workshop on Driving Impact: Uniting for MS Policy Change across the EU and National level, part of EMSP’s Membership…

MCB: Online Community Building

The Workshop on Online Community Building, part of EMSP’s Membership Capacity Building (MCB) Programme, was held in 2020 during the…

Expert advice on exercising as a person with MS

Adopting a fitness routine with Multiple Sclerosis (MS) presents unique challenges. While research clearly shows the positive impact of exercise…

EMA regulatory perspective – European Parliament debate on Real World Data

In this resource, we explore the European Medicines Agency’s (EMA) regulatory perspective on the use of real‑world data (RWD), as…

1 2